People · Operator
Named in public records as an officer, director or promoter · active 2012–2026 · Biotechnology, Pharmaceuticals, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alzheon, Inc. | — | Biotechnology | Series D+ | $172.5M | $1.6B | 2016 |
| Quoin Pharmaceuticals, Ltd. | — | Pharmaceuticals | Series D+ | $113.8M | $773.6M | 2022 |
| Empirico Inc. | — | Biotechnology | Series C | $74.8M | $665.0M | 2023 |
| Light Sciences Oncology Inc | — | Biotechnology | Series B | $45.0M | $80.4M | 2012 |
| NexEos Diagnostics, Inc. | — | Medical Devices | Series A | $25.7M | $7.9M | 2021 |
| Sancilio & Company, Inc. | — | Pharmaceuticals | Series B | $22.3M | $680.1M | 2012 |
| Avicenna Biosciences, Inc. | — | Biotechnology | Series A | $17.5M | $31.5M | 2022 |
| Sancilio Pharmaceuticals Company, Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2018 |
| Quoin Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $2.7M | $52.0M | 2021 |
Dennis Langer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dennis Langer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Gray | 2 | 10 |
| John Hamer | 2 | 7 |
| Jeff Himawan | 2 | 4 |
| Frederick Sancilio | 2 | 4 |
| Denise Carter | 2 | 2 |
| Natalie Leong | 2 | 2 |
| Peter Bisgaard | 1 | 9 |
| Stephen Tullman | 1 | 7 |
| Scott Minick | 1 | 7 |
| Franklin Berger | 1 | 7 |
| Terry Gould | 1 | 6 |
| Franz Hefti | 1 | 6 |
| Michael Myers | 1 | 5 |
| Robert Silverman | 1 | 5 |
| Christopher Noel Dunn | 1 | 5 |
| Michael Meyers | 1 | 5 |
| David Nikodem | 1 | 4 |
| Michael Aceti | 1 | 4 |
| Roderick Jackson | 1 | 3 |
| Dennis H. Langer | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.